ALOPM Stock Overview
Oncodesign Precision Medicine (OPM), a biopharmaceutical company, engages in the precision medicine business.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Oncodesign Precision Medicine Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.47 |
| 52 Week High | €2.39 |
| 52 Week Low | €1.00 |
| Beta | 0 |
| 1 Month Change | 0.68% |
| 3 Month Change | 8.89% |
| 1 Year Change | 40.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 72.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALOPM | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -3.6% | -0.4% | 0.002% |
| 1Y | 40.0% | -4.4% | 3.0% |
Return vs Industry: ALOPM exceeded the French Biotechs industry which returned -4.4% over the past year.
Return vs Market: ALOPM exceeded the French Market which returned 3% over the past year.
Price Volatility
| ALOPM volatility | |
|---|---|
| ALOPM Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.3% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALOPM's share price has been volatile over the past 3 months.
Volatility Over Time: ALOPM's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | opm.oncodesign.com |
Oncodesign Precision Medicine (OPM), a biopharmaceutical company, engages in the precision medicine business. It offers diagnostic and therapeutic solutions for resistant and metastatic cancers. The company is based in Dijon, France.
Oncodesign Precision Medicine Société anonyme Fundamentals Summary
| ALOPM fundamental statistics | |
|---|---|
| Market cap | €24.52m |
| Earnings (TTM) | -€8.10m |
| Revenue (TTM) | €1.80m |
13.6x
P/S Ratio-3.0x
P/E RatioIs ALOPM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALOPM income statement (TTM) | |
|---|---|
| Revenue | €1.80m |
| Cost of Revenue | €8.00m |
| Gross Profit | -€6.20m |
| Other Expenses | €1.90m |
| Earnings | -€8.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | -344.44% |
| Net Profit Margin | -450.00% |
| Debt/Equity Ratio | 0.0% |
How did ALOPM perform over the long term?
See historical performance and comparison